Moderate To Severe Genital Psoriasis clinical trials

Explore recruiting moderate to severe genital psoriasis clinical trials.

Also recruiting in Europe

Moderate To Severe Genital Psoriasis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TILD-24-01 : A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects with Moderate to Severe Genital Psoriasis

Hungary, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Moderate To Severe Genital Psoriasis trials by city

Moderate To Severe Genital Psoriasis in Toronto Moderate To Severe Genital Psoriasis in Vancouver Moderate To Severe Genital Psoriasis in Montreal Moderate To Severe Genital Psoriasis in Calgary Moderate To Severe Genital Psoriasis in Edmonton Moderate To Severe Genital Psoriasis in Ottawa Moderate To Severe Genital Psoriasis in Winnipeg Moderate To Severe Genital Psoriasis in Quebec City Moderate To Severe Genital Psoriasis in Hamilton Moderate To Severe Genital Psoriasis in Kitchener Moderate To Severe Genital Psoriasis in London Moderate To Severe Genital Psoriasis in Halifax Moderate To Severe Genital Psoriasis in New York Moderate To Severe Genital Psoriasis in Los Angeles Moderate To Severe Genital Psoriasis in Chicago Moderate To Severe Genital Psoriasis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease